CPRX vs. SDGR, SNDX, HRMY, AGIO, GPCR, EVO, AMRX, GLPG, EWTX, and SUPN
Should you be buying Catalyst Pharmaceuticals stock or one of its competitors? The main competitors of Catalyst Pharmaceuticals include Schrödinger (SDGR), Syndax Pharmaceuticals (SNDX), Harmony Biosciences (HRMY), Agios Pharmaceuticals (AGIO), Structure Therapeutics (GPCR), Evotec (EVO), Amneal Pharmaceuticals (AMRX), Galapagos (GLPG), Edgewise Therapeutics (EWTX), and Supernus Pharmaceuticals (SUPN). These companies are all part of the "pharmaceutical preparations" industry.
Schrödinger (NASDAQ:SDGR) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings, institutional ownership and community ranking.
79.1% of Schrödinger shares are owned by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 7.6% of Schrödinger shares are owned by company insiders. Comparatively, 11.0% of Catalyst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Catalyst Pharmaceuticals has a net margin of 17.93% compared to Catalyst Pharmaceuticals' net margin of -75.94%. Schrödinger's return on equity of 26.56% beat Catalyst Pharmaceuticals' return on equity.
In the previous week, Schrödinger had 13 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 15 mentions for Schrödinger and 2 mentions for Catalyst Pharmaceuticals. Schrödinger's average media sentiment score of 0.65 beat Catalyst Pharmaceuticals' score of -0.06 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.
Catalyst Pharmaceuticals received 434 more outperform votes than Schrödinger when rated by MarketBeat users. Likewise, 74.38% of users gave Catalyst Pharmaceuticals an outperform vote while only 55.17% of users gave Schrödinger an outperform vote.
Schrödinger has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500.
Schrödinger currently has a consensus price target of $42.80, indicating a potential upside of 80.74%. Catalyst Pharmaceuticals has a consensus price target of $26.43, indicating a potential upside of 79.54%. Given Catalyst Pharmaceuticals' higher possible upside, research analysts plainly believe Schrödinger is more favorable than Catalyst Pharmaceuticals.
Catalyst Pharmaceuticals has higher revenue and earnings than Schrödinger. Schrödinger is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Catalyst Pharmaceuticals beats Schrödinger on 13 of the 18 factors compared between the two stocks.
Get Catalyst Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Catalyst Pharmaceuticals Competitors List
Related Companies and Tools
